591 related articles for article (PubMed ID: 32506725)
41. SARS-CoV-2: A New Song Recalls an Old Melody.
Subbarao K
Cell Host Microbe; 2020 May; 27(5):692-694. PubMed ID: 32407706
[TBL] [Abstract][Full Text] [Related]
42. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
43. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
Khalaj-Hedayati A
J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833
[TBL] [Abstract][Full Text] [Related]
44. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
Bhattacharya M; Sharma AR; Patra P; Ghosh P; Sharma G; Patra BC; Lee SS; Chakraborty C
J Med Virol; 2020 Jun; 92(6):618-631. PubMed ID: 32108359
[TBL] [Abstract][Full Text] [Related]
45. Low risk of serological cross-reactivity between dengue and COVID-19.
Spinicci M; Bartoloni A; Mantella A; Zammarchi L; Rossolini GM; Antonelli A
Mem Inst Oswaldo Cruz; 2020; 115():e200225. PubMed ID: 32813814
[TBL] [Abstract][Full Text] [Related]
46. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
47. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV
Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356
[TBL] [Abstract][Full Text] [Related]
48. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages.
Maemura T; Kuroda M; Armbrust T; Yamayoshi S; Halfmann PJ; Kawaoka Y
mBio; 2021 Oct; 12(5):e0198721. PubMed ID: 34579572
[TBL] [Abstract][Full Text] [Related]
49. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
Stefano ML; Kream RM; Stefano GB
Med Sci Monit; 2020 May; 26():e926016. PubMed ID: 32463026
[TBL] [Abstract][Full Text] [Related]
50. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.
Coish JM; MacNeil AJ
Microbes Infect; 2020 Oct; 22(9):405-406. PubMed ID: 32590062
[TBL] [Abstract][Full Text] [Related]
51. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
[TBL] [Abstract][Full Text] [Related]
52. Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting.
Pontes RL; de Brito BB; da Silva FAF; Figueredo MS; Correia TML; Teixeira AF; Oliveira MV; de Melo FF
Travel Med Infect Dis; 2020; 37():101862. PubMed ID: 32858249
[No Abstract] [Full Text] [Related]
53. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.
Fu Y; Cheng Y; Wu Y
Virol Sin; 2020 Jun; 35(3):266-271. PubMed ID: 32125642
[TBL] [Abstract][Full Text] [Related]
54. LY6E impairs coronavirus fusion and confers immune control of viral disease.
Pfaender S; Mar KB; Michailidis E; Kratzel A; Boys IN; V'kovski P; Fan W; Kelly JN; Hirt D; Ebert N; Stalder H; Kleine-Weber H; Hoffmann M; Hoffmann HH; Saeed M; Dijkman R; Steinmann E; Wight-Carter M; McDougal MB; Hanners NW; Pöhlmann S; Gallagher T; Todt D; Zimmer G; Rice CM; Schoggins JW; Thiel V
Nat Microbiol; 2020 Nov; 5(11):1330-1339. PubMed ID: 32704094
[TBL] [Abstract][Full Text] [Related]
55. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
56. How the COVID-19 Overcomes the Battle? An Approach to Virus Structure.
Ahmadpour D; Ahmadpoor P
Iran J Kidney Dis; 2020 May; 14(3):167-172. PubMed ID: 32361692
[TBL] [Abstract][Full Text] [Related]
57. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
Ricke DO
Front Immunol; 2021; 12():640093. PubMed ID: 33717193
[TBL] [Abstract][Full Text] [Related]
58. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.
Nikolich-Zugich J; Knox KS; Rios CT; Natt B; Bhattacharya D; Fain MJ
Geroscience; 2020 Apr; 42(2):505-514. PubMed ID: 32274617
[TBL] [Abstract][Full Text] [Related]
59. Liver injury during highly pathogenic human coronavirus infections.
Xu L; Liu J; Lu M; Yang D; Zheng X
Liver Int; 2020 May; 40(5):998-1004. PubMed ID: 32170806
[TBL] [Abstract][Full Text] [Related]
60. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
